As proof-of-concept we used the BCR-ABL fusion product that is of paramount importance in chronic myeloid leukemia, showing the application potential in cancer diagnosis. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.